Faricimab

Genentech's Vabysmo improved vision in underrepresented populations with DME, showing clinically meaningful improvement in vision and reduction in retinal fluid, according to the ELEVATUM study. The study's efficacy and safety were consistent with previous Phase III DME studies, with Hispanic and Latino participants gaining an average of 14.1 letters and African American and Black participants gaining 11.3 letters from baseline after one year of treatment.

ELEVATUM study shows Vabysmo improves vision and reduces retinal fluid in African American, Black, Hispanic, and Latino DME patients, with safety consistent with phase III data.

Regeneron Pharmaceuticals faces headwinds with Eylea, its key eye disease treatment, due to biosimilar competition and a recent court decision favoring Amgen. Despite this, Regeneron's higher-dose Eylea and growth driver Dupixent, an eczema treatment, suggest resilience. Long-term biotech investors are advised to consider buying Regeneron shares on the dip.

Bispecific Antibodies Market size expected to surpass USD 40 billion by 2029, driven by innovative cancer therapies and increasing regulatory approvals.

Global bispecific antibody market valued > USD 8 billion in 2023, forecast to surpass USD 40 billion by 2030. 14 approved antibodies, led by Hemlibra and Vabysmo, dominate the market. US market generated > USD 5.5 billion in 2023, accounting for over 60% of total sales. Bispecific antibodies' unique mechanism positions them for complex disease treatment.

Bispecific antibodies market highlights include >30 development platforms, >USD 8B market size in 2023, and >800 clinical trials. Key approved antibodies like Blincyto and Hemlibra have seen significant sales. The market is driven by innovations in immuno-oncology, with ongoing trials by major pharma companies and research institutions globally.

XOMA Royalty announces FDA approval of MIPLYFFA™, the first therapy for NPC, entitling XOMA to a mid-single digit royalty on sales and up to $52.6 million in milestones, making it the sixth commercial asset in their portfolio.

FDA approves Regeneron's Dupixent for chronic rhinosinusitis with nasal polyps in adolescents aged 12-17, expanding its initial approval for adults. This expansion is supported by positive trial data showing significant improvements in symptoms and reduced need for corticosteroids or surgery.

Large drug-maker stocks surged, driven by FDA approvals and pipeline innovations. Eli Lilly, Roche, Novartis, and Pfizer are top picks for long-term gains. Eli Lilly's tirzepatide drugs and Novo Nordisk's semaglutide drugs are top sellers. Despite M&A scrutiny, activities remained strong. Large drug-makers offer robust revenue streams and profitability.

Chugai Pharmaceutical filed for an additional indication with MHLW for Vabysmo, targeting angioid streaks with neovascularization, receiving orphan drug designation. Based on a Japanese phase III study, Vabysmo demonstrated vision improvement, aiming to provide a new treatment option for this rare disease.